Clinical trials: Castrate Resistant Prostate Cancer
Prostate Cancer
QLC5508 in Participants With Metastatic Prostate Cancer
This is a randomized, open-label, active-controlled, multicenter Phase III trial evaluating QLC5508 versus docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after prior…
- Trial name
- NCT07632690
- Testing
- QLC5508, Docetaxel
- Volunteers
- 700 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostate Cancer
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
The purpose of this clinical trial is to find out the effect of epirubicin with estramustine phosphate and celecoxib on PSA and objective response in patients with hormone resistant prostate cancer as well as evaluating the…
- Trial name
- NCT00218205
- Testing
- Epirubicin, Estramustine Phosphate, Celecoxib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Department of Veterans Affairs, New Jersey
Metastatic Castration Resistant Prostate Cancer, mCRPC
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
- Trial name
- NCT07719361
- Testing
- FX-111
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Flare Therapeutics Inc.
Metastatic Castration-Resistant Prostate Cancer
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
The purpose of this study was to explore the safety and tolerability of enzalutamide in combination with abiraterone acetate plus prednisone.
- Trial name
- NCT01650194
- Testing
- enzalutamide, abiraterone acetate, prednisone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Castration Resistant Prostate Cancer
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
Background: Prostate cancer does not trigger a strong immune response in the body. Hormone therapy, to reduce levels of testosterone in the body, can be helpful to treat some prostate cancers.
- Trial name
- NCT05445882
- Testing
- Bintrafusp alfa, N-803, BN-Brachyury
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer, MCRPC, Cancer
Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.
- Trial name
- NCT06827080
- Testing
- 30 mCi NYMO32, 50 mCi NYMO32, 80 mCi NYMO32
- Volunteers
- 15 people
- Sponsor
- Zhengguo Chen
Prostate Cancer Metastatic to Bone
Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone.
- Trial name
- RaRe (NCT03458559)
- Testing
- Radium-223 chloride, Rhenium-188-HEDP
- Where
- Netherlands
- Volunteers
- 402 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Castration Resistant Prostate Cancer
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Main research purpose: To evaluate the effectiveness of Fluzoparib combined with apatinib mesylate in the treatment of patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT04869488
- Testing
- Fluzoparib, Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets, Fluzoparib Combined With Apatinib
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Prostatic Neoplasms
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
- Trial name
- NCT04428788
- Testing
- CC-94676, CC1083611, CC1083610
- Where
- 19 sites in United States
- Volunteers
- 131 people
- Sponsor
- Celgene
Breast Cancer, Prostate Cancer
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast…
- Trial name
- NCT07441889
- Testing
- HER2 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Prostatic Neoplasms
Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
To determine the feasibility and success rate of tumor tissue procurement using molecular-image-directed biopsies of responding and non-responding osseous metastases, measured by NaF PET/CT, in patients with metastatic…
- Trial name
- NCT02677376
- Testing
- 18F-Sodium Fluoride (NaF)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Wisconsin, Madison
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- AtezoCab (NCT05168618)
- Testing
- Atezolizumab, Cabozantinib S-malate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Utah
mCRPC
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
- Trial name
- TALAPRO-2 (NCT03395197)
- Testing
- Talazoparib with enzalutamide
- Where
- 370 sites in United States, Argentina and 24 more
- Volunteers
- 1,054 people
- Sponsor
- Pfizer
Prostate Cancer
TAK-700 in Castration Resistant Prostate Cancer
The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who…
- Trial name
- NCT01658527
- Testing
- Orteronel, Bicalutamide
- Where
- 4 sites in Belgium
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
This trial studies the effect of androgen receptor signaling inhibitors on 68Ga-PSMA-11 PET/CT imaging in patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04279561
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with…
- Trial name
- NCT00314782
- Testing
- ZD4054 (Zibotentan), Docetaxel
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Prostate Cancer
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic…
- Trial name
- NCT00003626
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Solid Malignancies, Metastatic Castrate-resistant Prostate Cancer
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
The main purpose of this study is to learn more about the safety of an investigational drug, axitinib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for…
- Trial name
- NCT01540526
- Testing
- axitinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
- Trial name
- NCT07104617
- Testing
- TY-302, Abiraptor
- Where
- China
- Volunteers
- 48 people
- Sponsor
- TYK Medicines, Inc